Publicacións en colaboración con investigadores/as de Hospital Universitario de la Princesa (8)

2022

  1. Enantioselective Synthesis and Pharmacological Evaluation of Aza‐CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease

    Antioxidants, Vol. 11, Núm. 1

2020

  1. Antioxidant, anti-inflammatory and neuroprotective profiles of novel 1,4-dihydropyridine derivatives for the treatment of alzheimer’s disease

    Antioxidants, Vol. 9, Núm. 8, pp. 1-20

  2. Aza-CGP37157-lipoic hybrids designed as novel Nrf2-inducers and antioxidants exert neuroprotection against oxidative stress and show neuroinflammation inhibitory properties

    Drug Development Research, Vol. 81, Núm. 3, pp. 283-294

  3. NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases

    Biomolecules, Vol. 10, Núm. 6

2017

  1. Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease

    Scientific Reports, Vol. 7

  2. ITH14001, a CGP37157-Nimodipine Hybrid Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts Neuroprotection in Cerebral Ischemia

    ACS Chemical Neuroscience, Vol. 8, Núm. 1, pp. 67-81

2014

  1. New 5-unsubstituted dihydropyridines with improved CaV1.3 selectivity as potential neuroprotective agents against ischemic injury

    Journal of Medicinal Chemistry, Vol. 57, Núm. 10, pp. 4313-4323

2013

  1. Identification of 4,6-diaryl-1,4-dihydropyridines as a new class of neuroprotective agents

    MedChemComm, Vol. 4, Núm. 3, pp. 590-594